In a report published Wednesday, Wedbush Securities analyst Zarak Khurshid reiterated a Neutral rating on EXACT Sciences Corporation EXAS, but lowered the price target from $19.00 to $18.00.
In the report, Wedbush Securities noted, "Maintaining NEUTRAL. Lowering PT from $19 to $18 on lower salesforce productivity and longer path to profitability. We are lowering our price target from $19 to $18 which is still based on a 2018E EV/sales basis (assuming ~5.5x vs 6x prior) and discount rate of 20%. We still believe our multiple is fair given the stellar regulatory & CMS progress, massive colorectal cancer opportunity, minimal competitive threats and strength of management. Based on our 2016E sales estimate of $148 MM, shares of EXAS are trading at an EV/sales multiple of ~15x, a premium to the group median of 3.2x."
EXACT Sciences closed on Tuesday at $22.90.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in